Nucleoside Analogues and Mitochondrial Toxicity

Russell Fleischer, Debra Boxwell, Kenneth E. Sherman

Clinical Infectious Diseases · 2004 · 128 citations · 2 references

DOIFull text

Open access

Concepts

Abstract

An evaluation of the US Food and Drug Administration's Adverse Event Reporting System identified that patients coinfected with human immunodeficiency virus and chronic hepatitis C virus who were treated with a regimen of ribavirin and didanosine, with or without stavudine, were at increased risk for events associated with mitochondrial toxicity, including fatal hepatic failure, peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis. In response, the US product labels for didanosine and ribavirin have been revised to caution clinicians against coadministration of these drugs.

References

2